Volume 33, Number 2 (May/June)

The International Diabetes Federation has attempted to estimate the prevalence of prediabetes, which is currently at 316 million people globally, although this is likely a dramatic underestimation. Prediabetes is a recognized risk factor for both diabetes and cardiovascular disease. Slowing the epidemic of diabetes, and its associated economic burden of microvascular and macrovascular complications, requires identification and treatment of prediabetes. This review will focus on the data using pharmacologic therapy to slow the progression from prediabetes to Type 2 diabetes.Drug treatmentPrediabetes

Current estimates indicate that at least 30% of the U.S. population has nonalcoholic fatty liver disease (NAFLD). With the increase in childhood obesity in the United States, this condition is being seen in not just adults but also children. Recent studies showing the high prevalence of NAFLD have led to the recognition that these patients are at increased risk for cardiovascular events, thus creating a clinical imperative for early diagnosis and early treatment of both NAFLD and the associated cardiovascular disease (CVD).Complications and comorbidities — Cardiovascular diseaseComplications and comorbidities — Liver complications

Vaccines play a central role in preventing serious infections in the entire population. But they are especially important for people with diabetes, who are more vulnerable to infections. Two vaccines in particular, pneumococcal and hepatitis B, are recommended specifically for people with diabetes.Complications and comorbidities — Insulinoma